🇺🇸 Clindamycin/benzoyl peroxide gel in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 27

Most-reported reactions

1. Acne — 6 reports (22.22%)
2. Drug Ineffective — 5 reports (18.52%)
3. Application Site Erythema — 3 reports (11.11%)
4. Application Site Dryness — 2 reports (7.41%)
5. Application Site Exfoliation — 2 reports (7.41%)
6. Application Site Pain — 2 reports (7.41%)
7. Application Site Pruritus — 2 reports (7.41%)
8. Application Site Rash — 2 reports (7.41%)
9. Drug Effect Decreased — 2 reports (7.41%)
10. Apnoea — 1 report (3.7%)

Source database →

Frequently asked questions

Is Clindamycin/benzoyl peroxide gel approved in United States?

Clindamycin/benzoyl peroxide gel does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Clindamycin/benzoyl peroxide gel in United States?

Actavis Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.